| | | really need to go into the tweets and read the links on the tweets which have the footnotes to the 1061 patient study.
The 80 patient study was too small--- this is better.
Is a significant reduction of patients who have serious progression and in mortality compared to global outcomes.
He's done a very good job looking at comorbities etc. The results are encouraging, but this will take time to work through. Larger trials should be helpful,,, but even so... at 1MM infected,,, that is still potentially 43,000 ventilators and ICU beds,,, if all of drug is available at all times,,, not striated for comorbidity,,, Those with hypertension fared much more poorly. So there will be questions. This will take weeks (starting from probably 2-3 weeks ago) not days to work through IMO,,, and in US, may be concern about who gets drug, how much vs. who doesn't which could hold things up.
In case of India,,,, i can see why they told Trump to fuck himself,,, see this paper.
ncbi.nlm.nih.gov
other notes:
1.) need for ventilators and severe progression is a bit ambiguous from current trends. presumption is as many as 4.4% required ventilation This is vs. ?
statnews.com
2.) Did a good job on inclusion criteria--which is a problem dependent on worldwide supply etc of both drugs.
3.) should open door for other antimalarials which may not be in short supply artemisinin, ivermectin,, etc.
Morbidity,,, is a bit of a problem for all data. Signs that many more are infected than previously thought(which is actually a good thing),,, can't say where that data is coming from only that it is being looked at in communities across USA.
To put all of this into a context:
usatoday.com
Cap it off with antiviral drugs hopeful,,, and this paints a very optimistic picture that an effective bridge between drugs and vaccines will happen. But still think we're in for some short term pain while the details are kicked around. |
|
